Literature DB >> 6791001

The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.

K Verebey.   

Abstract

The time-action of opiate antagonist activity of naltrexone was evaluated in detoxified ex-opiate addicts, using 25 mg intravenous heroin challenges. A 100 mg naltrexone dose provided 96% blockade at 24 hr, 86.5% blockade at 48 hr and 46.6% blockade at 72 hr. Following oral administration, naltrexone was rapidly and completely absorbed. Peak levels of naltrexone and its major metabolite 6 beta-naltrexol were reached 1 hr after the dose. The high 6 beta-naltrexol plasma concentrations only 1 hr after drug administration indicate a rapid biotransformation process, converting a large fraction of the dose to less active metabolites. Over 70% of the dose was excreted in the 24 hr urine and less than 0.5% in the feces. No change was observed in the rate of naltrexone disposition during chronic dosing vs. the acute study, indicating no metabolic induction. The rapid achievement of steady state naltrexone plasma levels eliminates the need of stepwise induction at the beginning of naltrexone treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6791001

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN: 1046-9516


  12 in total

1.  Naltrexone and problems in pain management.

Authors:  A P Vickers; A Jolly
Journal:  BMJ       Date:  2006-01-21

2.  Reduction of conditioned pain modulation in humans by naltrexone: an exploratory study of the effects of pain catastrophizing.

Authors:  Christopher D King; Burel Goodin; Lindsay L Kindler; Robert M Caudle; Robert R Edwards; Nikolaus Gravenstein; Joseph L Riley; Roger B Fillingim
Journal:  J Behav Med       Date:  2012-04-26

3.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

4.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

Review 5.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

6.  Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone.

Authors:  Charles P O'Brien; David R Gastfriend; Robert F Forman; Edward Schweizer; Helen M Pettinati
Journal:  Am J Addict       Date:  2010-12-28

7.  In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.

Authors:  Satyanarayana Valiveti; Kalpana S Paudel; Dana C Hammell; Mohamed O Hamad; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

8.  Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Jianyang Chen; Shashidhar K Akubathini; Irina O Beletskaya; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2011-07-18       Impact factor: 2.823

9.  Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program.

Authors:  Stephani L Stancil; William Adelman; Amanda Dietz; Susan Abdel-Rahman
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-07-16       Impact factor: 2.576

Review 10.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.